Botulinum toxin type B for sialorrhoea in children with cerebral palsy: A randomized trial comparing three doses

Developmental Medicine and Child Neurology

Volumn 53, Issue 6, 2011, Pages 559-564

  Basciani, Mario ^a   di Rienzo, Filomena ^a   Fontana, Andrea ^a   Copetti, Massimiliano ^a   Pellegrini, Fabio ^a,b   Intiso, Domenico ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b Scientific Institute IRCSS 'Casa Sollievo della Sofferenza' ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN B;

ARTICLE; ATAXIA; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPHAGIA; DYSTONIC DISORDER; FEMALE; GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM; HUMAN; HYPERSALIVATION; MALE; NEUROLOGIC DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUADRIPLEGIA; RANDOMIZED CONTROLLED TRIAL; SPASTIC PARAPLEGIA; XEROSTOMIA;

ADOLESCENT; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; SALIVARY GLANDS; SIALORRHEA;

EID: 79955982121     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2011.03952.x     Document Type: Article

References (25)

1. Krageloh-Mann I, Cans C. Cerebral palsy update. Brain Dev 2009; 31: 537-44.
2. Bachrach SJ, Walter RS, Trzcinski K. Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clin Pediatr (Phila) 1998; 37: 485-90.
3. Tscheng DZ. Sialorrhea - therapeutic drug options. Ann Pharmacother 2002; 36: 1785-90.
4. Blasco PA. Management of drooling: 10 years after the Consortium on Drooling, 1990. Dev Med Child Neurol 2002; 44: 778-81.
5. Crysdale WS, Raveh E, McCann C, Roske L, Kotler A. Management of drooling in individuals with neurodisability: a surgical experience. Dev Med Child Neurol 2001; 43: 379-83.
6. Bothwell JE, Clarke K, Dooley JM, et al. Botulinum toxin A as a treatment for excessive drooling in children. Pediatr Neurol 2002; 27: 18-22.
7. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for the treatment of drooling. Neurology 2003; 61: 1279-81.
8. Savarese R, Diamond M, Elovic E, Millis SR. Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil 2004; 83: 304-11.
9. Reid SM, Johnstone BR, Westbury C, Rawicki B, Reddihough DS. Randomized trial of botulinum toxin injections into salivary glands to reduce drooling in children with neurological disorders. Dev Med Child Neurol 2008; 50: 123-8.
10. Lin YC, Shieh JY, Cheng ML, Yang PY. Botulinum toxin type A for control of drooling in Asian patients with cerebral palsy. Neurology 2008; 70: 316-8.
11. Alrefai AH, Aburahma SK, Khader YS. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial. Clin Neurol Neurosurg 2009; 111: 79-82.
12. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62: 37-40.
13. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol 2009; 256: 563-7.
14. Costa J, Rocha ML, Ferreira J, Evangelista T, Coelho M, de Carvalho M. Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. J Neurol 2008; 255: 545-50.
15. Jackson CE, Gronseth G, Rosenfeld J, et al., Muscle Study Group Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009; 39: 137-43.
16. Steinlechner S, Klein C, Moser A, Lencer R, Hagenah J. Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea. Psychopharmacology (Berl) 2010; 207: 593-7.
17. Wilken B, Aslami B, Backes H. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics 2008; 39: 200-4.
18. Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 1988; 3: 73-8.
19. Van der Burg JJ, Jongerius PH, Van Hulst K, Van Limbeek J, Rotteveel JJ. Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and care. Dev Med Child Neurol 2006; 48: 103-7.
20. Lewis DW, Fontana C, Mehallick LK, Everett Y. Transdermal scopolamine for reduction of drooling in developmentally delayed children. Dev Med Child Neurol 1994; 36: 484-6.
21. Reddihough D, Johnson H, Staples M, Hudson I, Exarchos H. Use of benzhexol hydrochloride to control drooling of children with cerebral palsy. Dev Med Child Neurol 1990; 32: 985-9.
22. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003; 49: 34-8.
23. Racette BA, Lopate G, Good L, Sagitto S, Perlmutter JS. Ptosis as a remote effect of therapeutic botulinum toxin B injection. Neurology 2002; 59: 1445-7.
24. Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology 2005; 65: 765-7.
25. Berweck S, Schroeder AS, Lee SH, Bigalke H, Heinen F. Secondary non-response due to antibodies formation in a child after three injections of botulinum toxin B into salivary glands. Dev Med Child Neurol 2007; 49: 62-4.